Lesson plan
Radiprodil
Radiprodil ( ; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures. It is taken orally. The drug is being developed by GRIN Therapeutics. As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures. The drug was first described in the scientific literature by 2003.
Article summary
Radiprodil ( ; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures. It is taken orally. The drug is being developed by GRIN Therapeutics. As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures. The drug was first described in the scientific literature by 2003.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.